MRVI

$3.12

Post-MarketAs of Mar 17, 8:00 PM UTC

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$3.12
Potential Upside
5%
Whystock Fair Value$3.28
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.15B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-48.59%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
5.40

Recent News

Moby
Feb 26, 2026

Maravai LifeSciences Holdings, Inc. Q4 2025 Earnings Call Summary

Moby summary of Maravai LifeSciences Holdings, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Feb 26, 2026

Maravai LifeSciences Q4 Earnings Call Highlights

Maravai LifeSciences (NASDAQ:MRVI) executives told investors the company exited fiscal 2025 with improving operating leverage following a restructuring and a renewed emphasis on customer engagement, setting up management’s expectation for a return to growth and profitability in 2026. Fourth-quarter

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 26, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +40.03% and +1.21%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Feb 19, 2026

February 2026's Undervalued Small Caps With Insider Actions To Consider

As February 2026 begins, U.S. stock markets have shown resilience with major indices like the Dow Jones and S&P 500 ending sharply higher, buoyed by positive economic indicators such as an unexpected expansion in factory activity. In this dynamic environment, small-cap stocks present intriguing opportunities for investors seeking value and growth potential, especially when insider actions suggest confidence in a company's prospects amidst broader market optimism.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 16, 2026

Is There An Opportunity With Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 34% Undervaluation?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Maravai LifeSciences Holdings fair value estimate is US$4.51...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.